Head of Translational Genome Sciences
Dr. Michelle Penny has over 15 years’ experience in applying genetics across many different disease areas in the Pharmaceutical industry in Research and Development. She is co-chair of the National Academy of Sciences Roundtable on Genomics and Precision Health and the Industry Pharmacogenomics Working Group.
She received her Ph.D. in Genetics from the University of Birmingham, UK in 1993. After a postdoctoral fellowship in the Virology Division at the National Institute of Medical Research, Mill Hill, London, she joined Imperial College London, Department of Medical and Community Genetics where she was a postdoctoral research scientist until taking a lectureship in Human Molecular Genetics in 1998. Her academic research career focused on the study of complex polygenic diseases particularly autoimmune disease and susceptibility to infection. In 2002, Dr. Penny joined the Clinical Pharmacogenomics group at Pfizer in Sandwich, UK, and moved to New London, CT, USA in 2006 to take on the role of Oncology Molecular Medicine Lead until 2009 when she moved to Indianapolis to lead the Pharmacogenomics work at Eli Lilly and Company.
Michelle joined the Computational Biology and Genomics group at Biogen in 2015, where she now leads a Translational Genome Sciences Group that comprises, NGS and functional genomics labs, genome informatics, scientific computing and genomic biomarkers groups, that provide genomic data, analysis and interpretation to projects teams, with the goal of increasing the probability of success of Biogen’s neuroscience portfolio.